GE Stock DD General Electric Co. Sunday, April 27, 2014 8:51:47

New Post Public Reply Private Reply Replies (0) Message Board

Apr 27, 2014 at 9:51 PM

GE General Electric Co. $GE Company Overview

Stock Message Board http://investorshangout.com/search?q=GE&t...mp;yt1=Go!

Last Updated: Sunday, April 27, 2014 8:51:47 PM

General Electric Co. GE Current Price and Quotes
Last Price 26.60
Previous Close 26.46 Open 26.57
Daily Range 26.55 - 26.80 52wk Range 21.91 - 28.09
Volume 33,753,008 Dividend 0.88
Average Vol (3m) 34,181,410 Yield 3.3
General Electric Co. GE

General Electric Co. GE
General Electric Co. GE

General Electric Co. GE

General Electric Co. GE Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 146,045,000 146,684,000 146,542,000 149,567,000
Cost of Revenue 79,817,000 77,167,000 71,190,000 74,725,000
Gross Profit 66,228,000 69,517,000 75,352,000 74,842,000
Operating Expenses

Research and Development - - - -
Sales, General and Admin. 35,143,000 35,897,000 36,841,000 38,033,000
Non-Recurring Items 4,818,000 3,832,000 3,930,000 7,085,000
Other - - - -
Operating Income 26,267,000 29,788,000 34,581,000 29,724,000
Income From Continuing Operations

Add'l Income/Expense Items - - - -
Earnings Before Interest and Tax 26,267,000 29,788,000 34,581,000 29,724,000
Interest Expense 10,116,000 12,407,000 14,422,000 15,537,000
Earnings Before Tax 16,151,000 17,381,000 20,159,000 14,187,000
Income Tax 676,000 2,534,000 5,745,000 1,039,000
Minority Interest 298,000 223,000 292,000 535,000
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 15,475,000 14,847,000 14,414,000 13,148,000
Non Recurring Events

Discontinued Operations (2,120,000) (983,000) 29,000 (969,000)
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 13,057,000 13,641,000 14,151,000 11,644,000
Preferred Stock and Other Adjustments - - (1,031,000) (300,000)
Net Income Applicable to Common Shareholders 13,057,000 13,641,000 13,120,000 11,344,000

General Electric Co. GE Recent News

Apr 25, 2014 GE Invests USD 24 Million in Welspun Renewables Energy's Solar Project
Apr 24, 2014 GE's Energy Investing Unit Exceeds $10 Billion Renewable Energy Milestone, Generating Clean Power, Jobs
Apr 24, 2014 GE Modernizes ComEd's Electrical Grid, Improves Reliability with Industry's First UL-Certified Smart Meters
Apr 24, 2014 ComEd Smart Meters - Produced by GE - Certified by UL
Apr 24, 2014 Ellis Medicine Winner of 2014 North America Enterprise Information and Master Data Management Excellence Award
Apr 24, 2014 GE Capital Sees U.S. Middle Market Expansion Leading to InterGrowth Conference
Apr 24, 2014 GE's Digital Energy Business Selects TESSCO Technologies as an Authorized Channel Partner and Distributor
Apr 24, 2014 GE Antares Capital Agents $166 Million Cross-Border Facility for Audax Group's Acquisition of Luminator Technology
Apr 23, 2014 GE Transportation Showcases Rail Software Technology at the Annual American Short Line and Regional Railroad Association Meeting 2014
Apr 23, 2014 GE Capital Leads $135 Million in Credit Facilities for King's Hawaiian

1
2
3
4
5
6
7
8
next >
last >>

GE General Electric Co. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=GE&t...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/GE/quote
Stock Chart http://www.otcmarkets.com/stock/GE/chart
Company Info http://www.otcmarkets.com/stock/GE/company-info
Recent News http://www.otcmarkets.com/stock/GE/news
Financials http://www.otcmarkets.com/stock/GE/financials
Filings and Disclosure http://www.otcmarkets.com/stock/GE/filings
Short Sales http://www.otcmarkets.com/stock/GE/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/GE/insider-transactions
Research Reports http://www.otcmarkets.com/stock/GE/research
Summary http://finance.yahoo.com/q?s=GE
Historical Prices http://finance.yahoo.com/q/hp?s=GE+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=GE
Basic Chart http://finance.yahoo.com/q/bc?s=GE+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=GE+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=GE+Headlines
Press Releases http://finance.yahoo.com/q/p?s=GE+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=GE+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=GE+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=GE+Industry
Major Holders http://finance.yahoo.com/q/mh?s=GE+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=GE+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=GE+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=GE
Balance Sheet http://finance.yahoo.com/q/bs?s=GE
Cash Flow http://finance.yahoo.com/q/cf?s=GE+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/GE
Market Watch http://www.marketwatch.com/investing/stock/GE
Bloomberg http://www.bloomberg.com/quote/GE:US
Morningstar http://quotes.morningstar.com/stock/s?t=GE
Bussinessweek http://investing.businessweek.com/research/st...?ticker=GE
Barchart http://www.barchart.com/quotes/stocks/GE
OTC Short Report http://otcshortreport.com/index.php?index=GE
Investopedia http://www.investopedia.com/markets/stocks/GE/?wa=0

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...